scholarly journals Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib

2020 ◽  
Vol 9 (10) ◽  
pp. 553-560
Author(s):  
Elena Soto ◽  
Christopher Banfield ◽  
Pankaj Gupta ◽  
Mark C. Peterson
Keyword(s):  
Atopic Dermatitis ◽  
Time Course ◽  
Pharmacodynamic Model ◽  
Janus Kinase ◽  
Severe Atopic Dermatitis ◽  
Janus Kinase 1

16466 Predictors of maintenance of response in patients with moderate to severe atopic dermatitis after oral Janus kinase 1 selective inhibitor abrocitinib interruption

2020 ◽  
Vol 83 (6) ◽  
pp. AB64
Author(s):  
Melinda J. Gooderham ◽  
Giampiero Girolomoni ◽  
Julian O’Neil Moore ◽  
Jonathan I. Silverberg ◽  
Madelyn Curto ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Selective Inhibitor ◽  
Janus Kinase ◽  
Severe Atopic Dermatitis ◽  
Janus Kinase 1

scholarly journals 554 The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD)

2018 ◽  
Vol 138 (5) ◽  
pp. S94 ◽  
Author(s):  
M. Gooderham ◽  
S. Forman ◽  
R. Bissonnette ◽  
J. Beebe ◽  
W. Zhang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Signs And Symptoms ◽  
Janus Kinase ◽  
Severe Atopic Dermatitis ◽  
Janus Kinase 1

scholarly journals Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib

2021 ◽  
Vol 7 ◽  
pp. 65-67
Author(s):  
Jannett Nguyen ◽  
Jennifer K. Chen ◽  
Golara Honari ◽  
Marlyanne Pol-Rodriguez ◽  
Justin M. Ko ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Janus Kinase ◽  
Severe Atopic Dermatitis ◽  
Janus Kinase 1 ◽  
Instructive Case

scholarly journals Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis

2021 ◽  
Vol 8 ◽  
Author(s):  
Michelle Le ◽  
Melissa Berman-Rosa ◽  
Feras M. Ghazawi ◽  
Marc Bourcier ◽  
Loretta Fiorillo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Atopic Dermatitis ◽  
Safety Profile ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Symptom Control ◽  
Janus Kinase ◽  
Severe Atopic Dermatitis ◽  
Eligibility Criteria ◽  
Janus Kinase Inhibitors

Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic class of targeted therapy to treat moderate-to-severe atopic dermatitis (AD).Objective: To review the efficacy, safety, and pharmacokinetic characteristics of oral JAKi in the treatment of AD.Methods: A PRISMA systematic review was conducted using MEDLINE, EMBASE (Ovid), and PubMed databases for studies assessing the efficacy, safety, and/or pharmacokinetic properties of oral forms of JAKi in the treatment of AD in pediatric or adult populations from inception to June 2021.Results: 496 papers were reviewed. Of 28 articles that underwent full text screening, 11 met our inclusion criteria for final qualitative review. Four studies examined abrocitinib; three studies examined baricitinib; three examined upadacitinib and one examined gusacitinib (ASN002). Significant clinical efficacy and a reassuring safety profile was reported for all JAKi agents reviewed. Rapid symptom control was reported for abrocitinib, baricitinib and upadacitinib.Limitations: Given the relatively limited evidence for each JAKi and the differences in patient eligibility criteria between studies, the data was not deemed suitable for a meta-analysis at this time.Conclusion: Given their ability to achieve rapid symptom control with a reassuring safety profile, we recommend considering the use of JAKi as a reliable systemic treatment option for adult patients with moderate-to-severe AD, who are unresponsive to topical or skin directed treatments.

26237 Baricitinib, an oral, reversible Janus kinase-1 and -2 inhibitor, for atopic dermatitis: Head and neck response from BREEZE-AD5

2021 ◽  
Vol 85 (3) ◽  
pp. AB91
Author(s):  
Robert Bissonnette ◽  
Neil Korman ◽  
Benjamin Lockshin ◽  
Na Lu ◽  
Yun-Fei Chen ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Head And Neck ◽  
Janus Kinase ◽  
Janus Kinase 1
Sign in / Sign up

Export Citation Format

Share Document